StreetInsider.com News Articles

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 12 May 2026 17:03:00 -0400

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs
Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor
Clinical readouts expected in the second half of 2026 across all three programs
Cash runway expected to fund operations into 2028

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the first quarter ended March 31, 2026, and provided a business update, including highlights of pipeline progress.

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 12 May 2026 17:03:00 -0400

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs
Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor
Clinical readouts expected in the second half of 2026 across all three programs
Cash runway expected to fund operations into 2028

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 12 May 2026 17:03:00 -0400

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs
Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor
Clinical readouts expected in the second half of 2026 across all three programs
Cash runway expected to fund operations into 2028

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 12 May 2026 17:03:00 -0400

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs
Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor
Clinical readouts expected in the second half of 2026 across all three programs
Cash runway expected to fund operations into 2028

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 12 May 2026 17:03:00 -0400

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs
Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor
Clinical readouts expected in the second half of 2026 across all three programs
Cash runway expected to fund operations into 2028

BBOT Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Tue, 12 May 2026 17:03:00 -0400

Announced encouraging preliminary safety and efficacy data across all three RAS-pathway inhibitor programs
Announced publication in Cancer Discovery highlighting preclinical data demonstrating BBO-11818 is a potent and selective pan-KRAS inhibitor
Clinical readouts expected in the second half of 2026 across all three programs
Cash runway expected to fund operations into 2028

Form 4 BridgeBio Oncology Thera For: May 10 Filed by: Beltran Pedro

Tue, 12 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260512/26477954.html

Form 4 BridgeBio Oncology Thera For: May 10 Filed by: Elmelech Idan

Tue, 12 May 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20260512/26477980.html

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 12 May 2026 16:05:00 -0400

SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on May 10, 2026 under BBOT’s 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in March 2026.

The employee received non-qualified stock options to purchase 32,675 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $7.66 per share, the closing price of BBOT’s common stock as reported by Nasdaq

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Tue, 12 May 2026 16:05:00 -0400

Canaccord Starts BridgeBio Oncology Therapeutics, In (BBOT) at Buy

Mon, 11 May 2026 05:17:51 -0400

Canaccord analyst John Newman initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Buy rating and a price target of $23.00.

For an analyst ratings summary and ratings history on BridgeBio Oncology Therapeutics, In click here. For more ratings news on BridgeBio Oncology Therapeutics, In click here.

Shares of BridgeBio Oncology Therapeutics, In closed at $7.66 yesterday.

Canaccord Starts BridgeBio Oncology Therapeutics, In (BBOT) at Buy

Mon, 11 May 2026 05:17:51 -0400

Canaccord analyst John Newman initiates coverage on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT) with a Buy rating and a price target of $23.00.

For an analyst ratings summary and ratings history on BridgeBio Oncology Therapeutics, In click here. For more ratings news on BridgeBio Oncology Therapeutics, In click here.

Shares of BridgeBio Oncology Therapeutics, In closed at $7.66 yesterday.

Form 4 BridgeBio Oncology Thera For: Apr 01 Filed by: Ben Yong

Tue, 05 May 2026 19:06:00 -0400

si-local-file:///var/storage/secattach/20260505/26436994.html

Form 4 BridgeBio Oncology Thera For: Apr 01 Filed by: Beltran Pedro

Tue, 05 May 2026 19:03:00 -0400

si-local-file:///var/storage/secattach/20260505/26436990.html

Form 4 BridgeBio Oncology Thera For: Apr 01 Filed by: Mehra Uneek

Tue, 05 May 2026 19:02:00 -0400

si-local-file:///var/storage/secattach/20260505/26436984.html

Form 3 BridgeBio Oncology Thera For: Apr 21 Filed by: Cobo Marc

Thu, 30 Apr 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260430/26408468.html

Form 3 BridgeBio Oncology Thera For: Apr 20 Filed by: Elmelech Idan

Thu, 30 Apr 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260430/26408369.html

H.C. Wainwright Reiterates Buy Rating on BridgeBio Oncology Therapeutics, In (BBOT)

Fri, 24 Apr 2026 06:43:46 -0400

H.C. Wainwright analyst Robert Burns reiterated a Buy rating and $29.00 price target on BridgeBio Oncology Therapeutics, In (NASDAQ: BBOT).

The analyst commented: "At the recent annual AACR meeting, BridgeBio Oncology Therapeutics presented preclinical data for BBO-11818 (a pan-KRAS[ON/OFF] inhibitor) and BBO-10203 (a selective RAS:PI3K⍺ breaker). For BBO-11818, poster data showed BBO-11818 monotherapy produced potent, dose- and time-dependent inhibition of pERK in vitro, translating into robust anti-tumor activity in KRASG12D/V+ pancreatic, NSCLC, and CRC CDX models. Beyond monotherapy applications, combining BBO-11818 with BBO-10203 or an anti-PD1 mAb in KRASG12D/V+ CDX and PDX models yielded a statistically significant improvement in OS compared

BBOT presents preclinical data on pan-KRAS inhibitor BBO-11818

Wed, 22 Apr 2026 16:05:29 -0400

BridgeBio Oncology Therapeutics (NASDAQ: BBOT) presented preclinical data for its drug candidate BBO-11818 at the American Association for Cancer Research Annual Meeting 2026. The data showed the compound's anti-tumor activity in KRAS-mutant cancer models.

BBO-11818 is an orally bioavailable inhibitor that targets mutant KRAS protein in both its active and inactive states. The preclinical studies demonstrated the compound's ability to suppress MAPK signaling and inhibit cell proliferation in KRAS-mutant cell lines.

According to the presented data, BBO-11818 showed efficacy in pancreatic, lung, and colorectal cancer models containing KRAS G12D and KRAS G12V mutations. The compound also demonstrated combination activity when used with

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

Wed, 22 Apr 2026 16:05:00 -0400

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines

BBO-11818 demonstrates robust anti-tumor activity as monotherapy and in combination across KRAS-mutant tumor models

Updated Phase 1 clinical data are expected in the second half of 2026

SOUTH SAN FRANCISCO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today presented new preclinical data for BBO-11818, a selective, orally bioavailable non-covalent inhibitor that targets mutant KRAS

BBOT Presents Preclinical Data Demonstrating pan-KRAS Inhibitor BBO-11818 Has Robust Anti-Tumor Activity in KRAS-Mutant Preclinical Models at the AACR Annual Meeting 2026

Wed, 22 Apr 2026 16:05:00 -0400

BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potently suppressing MAPK signaling and inhibiting cell proliferation in KRAS-mutant cell lines

BBO-11818 demonstrates robust anti-tumor activity as monotherapy and in combination across KRAS-mutant tumor models

Updated Phase 1 clinical data are expected in the second half of 2026

BBOT names Pedro Beltran CEO, Idan Elmelech COO in leadership transition

Wed, 22 Apr 2026 09:00:12 -0400

BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) appointed Pedro J. Beltran as chief executive officer and Idan Elmelech as chief operating officer, effective April 20, according to a company statement.

Beltran, who previously served as BBOT's chief scientific officer, brings two decades of oncology drug development experience including roles at large pharmaceutical companies. He joined BridgeBio Pharma in 2020 as senior vice president of biology before becoming BBOT's chief scientific officer in July 2023. Prior positions include senior vice president, head of biology at UNITY Biotechnology and executive director, oncology research at Amgen Inc.

Elmelech transitions from his role as senior vice president

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Wed, 22 Apr 2026 09:00:00 -0400

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top executive

Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development

Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the

BBOT Announces the Appointment of Pedro J. Beltran, PhD, as Chief Executive Officer, Idan Elmelech as Chief Operating Officer, and Neil Kumar, PhD, as Executive Chairman

Wed, 22 Apr 2026 09:00:00 -0400

Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBOT, will assume the position of Chief Executive Officer, bringing his extensive drug development experience and scientific/business acumen to bear as the company’s top executive

Idan Elmelech, who previously served as Senior Vice President of Strategy & Business Development, will assume the position of Chief Operating Officer overseeing finance & accounting, corporate strategy, operations, and business development

Neil Kumar, PhD, who played an integral role in the founding of BBOT as part of BridgeBio Pharma, Inc., has been appointed as Executive Chairman by the

BBOT presents preclinical data for cancer drug BBO-10203 at AACR meeting

Tue, 21 Apr 2026 17:30:29 -0400

BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) presented preclinical data for its experimental cancer drug BBO-10203 at the American Association for Cancer Research Annual Meeting 2026. The company reported that the drug disrupts the interaction between RAS and PI3Kα proteins, leading to signaling inhibition in cancer cells without causing hyperglycemia.

According to the company's presentation, BBO-10203 induced tumor regressions at a 30 mg/kg daily dose and showed no hyperglycemia at 100 mg/kg daily in preclinical studies. The drug demonstrated combination effects with HER2 inhibitors tucatinib and trastuzumab in HER2-amplified cancer models.

Pedro J. Beltran, Chief Scientific Officer of BBOT, stated that BBO-10203's mechanism